Related Experiment Video
Updated: Aug 3, 2025
09:01
Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach
Published on: June 5, 2010
14.3K
Inclusion body myositis triggerred with long-term imatinib use
Rabia Deniz1,2, Tevfik Güzelbey3, Sanem Narinoğlu4
1Department of Rheumatology, University of Health Sciences Başakşehir Çam and Sakura City Hospital, Istanbul, Turkey.
Summary
This case report details the first instance of inclusion body myositis (IBM) linked to long-term imatinib use. Discontinuing imatinib improved the patient's weight loss and muscle weakness, highlighting a potential drug-induced myopathy.
Area of Science:
- Neurology
- Oncology
- Pharmacology
Background:
- Imatinib is a tyrosine kinase inhibitor used for various cancers.
- Inclusion body myositis (IBM) is an acquired inflammatory and degenerative myopathy.
Observation:
- An 81-year-old male on long-term imatinib for gastrointestinal stromal tumor (GIST) presented with rapid, severe muscle weakness and weight loss.
- Physical exam revealed asymmetrical muscle atrophy, normal creatine kinase, and MRI/EMG findings suggestive of myositis.
- Quadriceps biopsy confirmed IBM, with imatinib identified as the sole potential trigger.
Findings:
- This is the first reported case of IBM associated with prolonged imatinib therapy.
- Discontinuation of imatinib led to significant clinical improvement in muscle strength and weight.
Implications:
- Awareness of imatinib-induced IBM is crucial due to the drug's widespread use.
- Identifying imatinib as the etiology is key for managing IBM, especially given its poor response to standard immunosuppressants.
Related Concept Videos
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
01:20Myasthenia Gravis: Overview and Treatment
1.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.7K